Ethic Inc. Buys New Stake in Ascendis Pharma A/S $ASND

Ethic Inc. bought a new stake in Ascendis Pharma A/S (NASDAQ:ASND) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 10,326 shares of the biotechnology company’s stock, valued at approximately $2,353,000.

A number of other large investors also recently added to or reduced their stakes in ASND. Allworth Financial LP lifted its stake in Ascendis Pharma A/S by 103.4% during the second quarter. Allworth Financial LP now owns 240 shares of the biotechnology company’s stock worth $64,000 after purchasing an additional 122 shares in the last quarter. EverSource Wealth Advisors LLC lifted its stake in Ascendis Pharma A/S by 34.0% during the 1st quarter. EverSource Wealth Advisors LLC now owns 272 shares of the biotechnology company’s stock worth $62,000 after acquiring an additional 69 shares in the last quarter. Parallel Advisors LLC boosted its holdings in Ascendis Pharma A/S by 94.9% during the 1st quarter. Parallel Advisors LLC now owns 304 shares of the biotechnology company’s stock valued at $70,000 after acquiring an additional 148 shares during the period. IFP Advisors Inc boosted its holdings in Ascendis Pharma A/S by 3,491.7% during the 2nd quarter. IFP Advisors Inc now owns 431 shares of the biotechnology company’s stock valued at $115,000 after acquiring an additional 419 shares during the period. Finally, Farther Finance Advisors LLC acquired a new position in Ascendis Pharma A/S in the 3rd quarter valued at about $139,000.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on ASND. BMO Capital Markets reiterated an “outperform” rating on shares of Ascendis Pharma A/S in a research note on Thursday, September 10th. Morgan Stanley reduced their price target on shares of Ascendis Pharma A/S from $275.00 to $273.00 and set an “overweight” rating on the stock in a research report on Tuesday, September 1st. Bank of America lowered their price objective on shares of Ascendis Pharma A/S from $306.00 to $304.00 and set a “buy” rating for the company in a research note on Monday, August 31st. Raymond James Financial cut shares of Ascendis Pharma A/S from a “strong-buy” rating to an “outperform” rating and set a $287.00 price objective for the company. in a report on Tuesday, September 15th. Finally, Citigroup cut their target price on shares of Ascendis Pharma A/S from $360.00 to $330.00 and set a “buy” rating on the stock in a research note on Monday, October 26th. Nineteen investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $305.95.

Insider Buying and Selling

In other Ascendis Pharma A/S news, SVP Mads Bodenhoff sold 3,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $270.19, for a total transaction of $810,570.00. Following the completion of the transaction, the senior vice president owned 3,000 shares in the company, valued at $810,570. The trade was a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Jean-Jacques Bienaimé purchased 2,000 shares of the stock in a transaction on Friday, August 14th. The shares were purchased at an average price of $246.33 per share, with a total value of $492,660.00. Following the acquisition, the director directly owned 2,900 shares in the company, valued at $714,357. This represents a 222.22% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 40.00% of the stock is owned by insiders.

Ascendis Pharma A/S Stock Performance

Shares of Ascendis Pharma A/S stock opened at $259.28 on Thursday. Ascendis Pharma A/S has a one year low of $188.07 and a one year high of $282.15. The company has a market cap of $16.17 billion, a PE ratio of 20.11 and a beta of 0.40. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.32 and a current ratio of 2.99. The business has a 50-day simple moving average of $242.59 and a 200-day simple moving average of $239.48.

Ascendis Pharma A/S (NASDAQ:ASND) last released its earnings results on Friday, August 14th. The biotechnology company reported $1.03 earnings per share for the quarter, missing analysts’ consensus estimates of $1.71 by ($0.68). The firm had revenue of $387.22 million for the quarter, compared to analysts’ expectations of $376.75 million. Ascendis Pharma A/S had a return on equity of 32.54% and a net margin of 70.99%. On average, equities research analysts forecast that Ascendis Pharma A/S will post 3.43 EPS for the current fiscal year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a biopharmaceutical company headquartered in Denmark that develops medicines for rare diseases, with a focus on endocrinology. Founded in 2006, the company uses its TransCon technology platform to design therapies intended to provide sustained delivery of medicines. Its commercial products include SKYTROFA (lonapegsomatropin), a once-weekly growth hormone treatment for children with growth hormone deficiency, and YORVIPATH (palopegteriparatide), a treatment for adults with hypoparathyroidism.